BioCryst Pharmaceuticals, Inc.
BCRX
$10.34
$0.505.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 218.25M | 156.41M | 406.56M | 159.40M | 163.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 218.25M | 156.41M | 406.56M | 159.40M | 163.35M |
| Cost of Revenue | 55.81M | 65.70M | 48.35M | 46.79M | 46.18M |
| Gross Profit | 162.44M | 90.72M | 358.21M | 112.61M | 117.17M |
| SG&A Expenses | 63.98M | 94.55M | 91.51M | 83.01M | 87.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 119.79M | 160.25M | 139.86M | 129.80M | 133.57M |
| Operating Income | 98.47M | -3.84M | 266.70M | 29.59M | 29.79M |
| Income Before Tax | 79.47M | -720.81M | 248.02M | 12.13M | 6.49M |
| Income Tax Expenses | 1.08M | 1.00M | 2.17M | -769.00K | 1.40M |
| Earnings from Continuing Operations | 78.40M | -721.81M | 245.85M | 12.90M | 5.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 78.40M | -721.81M | 245.85M | 12.90M | 5.09M |
| EBIT | 98.47M | -3.84M | 266.70M | 29.59M | 29.79M |
| EBITDA | 98.98M | -2.78M | 267.55M | 31.57M | 30.12M |
| EPS Basic | 0.31 | -2.98 | 1.17 | 0.06 | 0.02 |
| Normalized Basic EPS | 0.20 | -0.06 | 0.77 | 0.04 | 0.03 |
| EPS Diluted | 0.30 | -2.98 | 1.13 | 0.06 | 0.02 |
| Normalized Diluted EPS | 0.19 | -0.06 | 0.74 | 0.04 | 0.03 |
| Average Basic Shares Outstanding | 254.48M | 242.26M | 210.97M | 210.18M | 209.52M |
| Average Diluted Shares Outstanding | 265.17M | 242.26M | 219.26M | 219.89M | 219.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |